VEGFA and hepatocellular carcinoma: Lenvatinib, an angiogenesis inhibitor, inhibits VEGF and tumor fibroblast growth factor signaling pathways in unresectable HCC.25 The synergistic effect of the combination can inhibit tumor growth more effectively.